Key Inclusion Criteria:

   - Previously treated individuals with inoperable metastatic colorectal cancer (mCRC) who
   are ineligible for checkpoint inhibitor therapy (microsatellite instability (MSI)-H or
   mismatch repair deficient (dMMR) and are excluded).

   - Histologically or cytologically confirmed adenocarcinoma originating in the colon or
   rectum (excluding appendiceal and anal canal cancers) who have progressed on or after
   1 prior systemic therapy in the setting where curative resection is not indicated.
   This therapy must have included chemotherapy based on 5-FU or capecitabine with
   oxaliplatin and either bevacizumab, or for patients with RAS wild-type and left-sided
   tumors, bevacizumab, cetuximab, or panitumumab.

   - Measurable disease (RECIST V1.1 criteria).

   - Individuals must have an eastern cooperative oncology group (ECOG) performance status
   of 0 or 1.

   - Life expectancy of at least 12 weeks.

   - Laboratory measurements, blood counts: adequate hemoglobin, neutrophil, and platelet
   counts

   - Adequate liver function.

   - Adequate renal function.

Key Exclusion Criteria:

   - Prior anticancer therapy including chemotherapy, hormonal therapy, or investigational
   agents within 3 weeks or within at least 4 half-lives prior to magrolimab dosing (up
   to a maximum of 4 weeks), whichever is shorter.

   - Known v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E or MSI-H mutations
   or dMMR.

   - Persistent Grade 2 or more gastrointestinal bleeding.

   - Individuals with prior irinotecan therapy.

   - Clinically significant coronary artery disease or myocardial infarction within 6
   months prior to inclusion.

   - Peripheral neuropathy of more than Grade 2 (CTCAE Version 5.0).

   - Known dihydropyrimidine dehydrogenase deficiency.

   - Acute intestinal obstruction or subobstruction, history of inflammatory intestinal
   disease or extended resection of the small intestine. Presence of a colonic
   prosthesis.

   - Unhealed wound, active gastric or duodenal ulcer, or bone fracture.

   - History of abdominal fistulas, trachea-oesophageal fistulas, any other Grade 4
   gastrointestinal perforations, nongastrointestinal fistulas, or intra-abdominal
   abscesses 6 months prior to screening.

   - Uncontrolled arterial hypertension.

   - Thromboembolic event in the 6 months before inclusion (eg, transitory ischemic stroke,
   stroke, subarachnoid hemorrhage) except peripheral deep vein thrombosis treated with
   anticoagulants.

   - Active central nervous system (CNS) disease. Individuals with asymptomatic and stable,
   treated CNS lesions (radiation and/or surgery and/or other CNS-directed therapy who
   have not received corticosteroids for at least 4 weeks) are allowed.

   - Red blood cell (RBC) transfusion dependence, defined as requiring more than 2 units of
   packed RBC transfusions during the 4-week period prior to screening.

   - History of hemolytic anemia, autoimmune thrombocytopenia, or Evans syndrome in the
   last 3 months.

   - Known hypersensitivity to any of the study drugs, the metabolites, or formulation
   excipient.

   - Known inherited or acquired bleeding disorders.

   - Significant disease or medical conditions, as assessed by the investigator and
   sponsor, that would substantially increase the risk-benefit ratio of participating in
   the study.

   - Second malignancy, except treated basal cell or localized squamous skin carcinomas, or
   localized prostate cancer.

   - Uncontrolled pleural effusion.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.